Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - mačke - aktivna imunizacija mačaka starijih od 12 tjedana kako bi se spriječila smrtnost zbog zaraze bjesnoće. početak imuniteta: 4 tjedna nakon primarnog cijepljenja. trajanje imuniteta nakon primarne cijepljenja: 1 godina. trajanje imunosti nakon ponovne vakcinacije: 3 godine.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - Рекомбинантный герпесвирус turske, procijediti vhvt013-69, živjeti - imunomodulatori za ptice, domaće peradi, imunomodulatori - embryonated eggs; chicken - za aktivna imunizacija pilića:za sprečavanje smrtnosti i smanjenje kliničkih znakova i poraza zaraznih bolesti Бурсальной . smanjiti smrtnost, klinički znakovi i poraza bolest Марека .

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamithromycin - antibakterijska sredstva za sistemsku uporabu - cattle; pigs; sheep - cattletreatment i метафилактики goveđa respiratorne bolesti (БРД), povezana je s mannheimia haemolytica, bakterija pasteurella multocida i histophilus odaberite somni. prisutnost bolesti u stadu treba biti uspostavljena prije metafilaktičke uporabe. pigstreatment respiratorne bolesti svinja (СРД), povezana je sa actinobacillus плевропневмонии, bakterija pasteurella multocida i haemophilus parasuis i Бордетеллы bronchiseptica. sheeptreatment zaraznih pododermatitis (копытная trulež), povezana je s virulentnih пилей dichelobacter nodosus i fusobacterium necrophorum, koji zahtijevaju sustava liječenja.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - svinjski circovirus tip 2 orf2 proteina - imunološke za suidae - svinje - za aktivne imunizacije svinja sa ЦВС2 primljenih mothered antitijela u dobi od 2 tjedna protiv svinjske цирковирус tipa 2 (ЦВС2),.

Euroopa Liit - horvaadi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - hrskavičav inducirana periferne krvi konja аллогенных мезенхимальных matičnih stanica - ostali lijekovi za poremećaje mišićno-koštanog sustava - konji - smanjenje od blage do umjerene relaps хромотой povezane s септическим upalom zglobova u konja.